BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yoshikawa T, Rino Y, Yukawa N, Oshima T, Tsuburaya A, Masuda M. Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy. Surg Today. 2014;44:11-21. [PMID: 23508452 DOI: 10.1007/s00595-013-0529-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Oshima T, Yoshikawa T, Miyagi Y, Morita S, Yamamoto M, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, Yokose T, Hiroshima Y, Aoyama T, Hayashi T, Ogata T, Cho H, Rino Y, Masuda M, Tsuburaya A, Sakamoto J. Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial. Oncotarget 2020;11:2906-18. [PMID: 32774771 DOI: 10.18632/oncotarget.27658] [Reference Citation Analysis]
2 Urakawa S, Sakai D, Miyazaki Y, Kudo T, Katou A, Inagaki C, Tanaka K, Makino T, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Satoh T, Mori M, Doki Y. A case of ramucirumab-related gastrointestinal perforation in gastric cancer with small bowel metastasis. Surg Case Rep 2017;3:127. [PMID: 29260338 DOI: 10.1186/s40792-017-0399-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Maezawa Y, Aoyama T, Kano K, Tamagawa H, Numata M, Hara K, Murakawa M, Yamada T, Sato T, Ogata T, Oshima T, Yukawa N, Yoshikawa T, Masuda M, Rino Y. Impact of the Age-adjusted Charlson comorbidity index on the short- and long-term outcomes of patients undergoing curative gastrectomy for gastric cancer. J Cancer 2019;10:5527-35. [PMID: 31632496 DOI: 10.7150/jca.35465] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
4 Jiang ZY, Kinami S, Nakamura N, Miyata T, Fujita H, Takamura H, Ueda N, Kosaka T. Diagnostic ability of multi-detector spiral computed tomography for pathological lymph node metastasis of advanced gastric cancer. World J Gastrointest Oncol 2020;12:435-46. [PMID: 32368321 DOI: 10.4251/wjgo.v12.i4.435] [Reference Citation Analysis]
5 Nakazono M, Aoyama T, Hayashi T, Hara K, Segami K, Shimoda Y, Nagasawa S, Kumazu Y, Yamada T, Tamagawa H, Shiozawa M, Morinaga S, Rino Y, Masuda M, Ogata T, Oshima T. Comparison of the Dietary Intake Loss Between Total and Distal Gastrectomy for Gastric Cancer. In Vivo 2021;35:2369-77. [PMID: 34182520 DOI: 10.21873/invivo.12514] [Reference Citation Analysis]
6 Yamaoka Y, Fujitani K, Tsujinaka T, Yamamoto K, Hirao M, Sekimoto M. Skeletal muscle loss after total gastrectomy, exacerbated by adjuvant chemotherapy. Gastric Cancer. 2015;18:382-389. [PMID: 24715254 DOI: 10.1007/s10120-014-0365-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
7 Yoshikawa T, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, Hasegawa S, Aoyama T, Hayashi T, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J. Accuracy of CT staging of locally advanced gastric cancer after neoadjuvant chemotherapy: cohort evaluation within a randomized phase II study. Ann Surg Oncol. 2014;21 Suppl 3:S385-S389. [PMID: 24595801 DOI: 10.1245/s10434-014-3615-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
8 Kaltenmeier C, Althans A, Mascara M, Nassour I, Khan S, Hoehn R, Zureikat A, Tohme S. Pathologic Complete Response Following Neoadjuvant Therapy for Gastric Adenocarcinoma: A National Cancer Database Analysis on Incidence, Predictors, and Outcomes. Am Surg 2021;87:1145-54. [PMID: 33342268 DOI: 10.1177/0003134820972083] [Reference Citation Analysis]
9 Kodera Y, Kobayashi D, Tanaka C, Fujiwara M. Gastric adenocarcinoma with para-aortic lymph node metastasis: A borderline resectable cancer? Surg Today. 2015;45:1082-1090. [PMID: 25366353 DOI: 10.1007/s00595-014-1067-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
10 Braga Mendonça A, Ramos Pereira E, Magnago C, Andrade Silva RMCR, das Graças Gazel de Souza M, de Lima Cury Cunha MA. Distress in the context of cancer and chemotherapy: A mixed-method study. Int J Nurs Pract 2021;:e12949. [PMID: 34101309 DOI: 10.1111/ijn.12949] [Reference Citation Analysis]
11 Yang Y, Yin X, Sheng L, Xu S, Dong L, Liu L. Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated Meta-analysis. Sci Rep 2015;5:12850. [PMID: 26242393 DOI: 10.1038/srep12850] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
12 Yamamoto M, Takahashi T, Serada S, Sugase T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Naka T, Mori M, Doki Y. Overexpression of leucine-rich α2-glycoprotein-1 is a prognostic marker and enhances tumor migration in gastric cancer. Cancer Sci 2017;108:2052-60. [PMID: 28746773 DOI: 10.1111/cas.13329] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
13 Aoyama T, Yoshikawa T. Adjuvant therapy for locally advanced gastric cancer. Surg Today. 2017;47:1295-1302. [PMID: 28251375 DOI: 10.1007/s00595-017-1493-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
14 Honma Y, Yamada Y, Terazawa T, Takashima A, Iwasa S, Kato K, Hamaguchi T, Shimada Y, Ohashi M, Morita S, Fukagawa T, Machida N, Katai H. Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinoma. Surg Today 2016;46:1076-82. [PMID: 26563224 DOI: 10.1007/s00595-015-1276-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
15 Hashemzadeh S, Pourzand A, Somi MH, Zarrintan S, Javad-Rashid R, Esfahani A. The effects of neoadjuvant chemotherapy on resectability of locally-advanced gastric adenocarcinoma: a clinical trial. Int J Surg. 2014;12:1061-1069. [PMID: 25157992 DOI: 10.1016/j.ijsu.2014.08.349] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
16 Miyazaki Y, Takiguchi S, Takahashi T, Kurokawa Y, Makino T, Yamasaki M, Nakajima K, Mori M, Doki Y. Treatment of gastric outlet obstruction that results from unresectable gastric cancer: Current evidence. World J Gastrointest Endosc. 2016;8:165-172. [PMID: 26862366 DOI: 10.4253/wjge.v8.i3.165] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
17 Tahara T, Shibata T, Okubo M, Kawamura T, Horiguchi N, Yoshida D, Ishizuka T, Nagasaka M, Nakagawa Y, Ohmiya N. Evaluations of primary lesions by endoscopy clearly distinguishes prognosis in patients with gastric cancer who receive chemotherapy. PLoS One 2017;12:e0173663. [PMID: 28288188 DOI: 10.1371/journal.pone.0173663] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
18 Yoshikawa T, Morita S, Tanabe K, Nishikawa K, Ito Y, Matsui T, Fujitani K, Kimura Y, Fujita J, Aoyama T, Hayashi T, Cho H, Tsuburaya A, Miyashita Y, Sakamoto J. Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer. Eur J Cancer. 2016;62:103-111. [PMID: 27244537 DOI: 10.1016/j.ejca.2016.04.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
19 Wang QW, Zhang XT, Lu M, Shen L. Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer. World J Gastrointest Oncol 2018;10:31-9. [PMID: 29375746 DOI: 10.4251/wjgo.v10.i1.31] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
20 Guner A, Yildirim R. Surgical management of metastatic gastric cancer: moving beyond the guidelines. Transl Gastroenterol Hepatol 2019;4:58. [PMID: 31559339 DOI: 10.21037/tgh.2019.08.03] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
21 Cho H, Nakamura J, Asaumi Y, Yabusaki H, Sakon M, Takasu N, Kobayashi T, Aoki T, Shiraishi O, Kishimoto H. Long-term survival outcomes of advanced gastric cancer patients who achieved a pathological complete response with neoadjuvant chemotherapy: a systematic review of the literature. Ann Surg Oncol. 2015;22:787-792. [PMID: 25223927 DOI: 10.1245/s10434-014-4084-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
22 Ju C, Wen Y, Zhang L, Wang Q, Xue L, Shen J, Zhang C. Neoadjuvant Chemotherapy Based on Abraxane/Human Neutrophils Cytopharmaceuticals with Radiotherapy for Gastric Cancer. Small 2019;15:1804191. [DOI: 10.1002/smll.201804191] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
23 Aoyama T, Yoshikawa T, Sato T, Hayashi T, Yamada T, Ogata T, Cho H. Equivalent feasibility and safety of perioperative care by ERAS in open and laparoscopy-assisted distal gastrectomy for gastric cancer: a single-institution ancillary study using the patient cohort enrolled in the JCOG0912 phase III trial. Gastric Cancer 2019;22:617-23. [PMID: 30194500 DOI: 10.1007/s10120-018-0873-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
24 Aoyama T, Kawabe T, Fujikawa H, Hayashi T, Yamada T, Tsuchida K, Yukawa N, Oshima T, Rino Y, Masuda M, Ogata T, Cho H, Yoshikawa T. Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer. Ann Surg Oncol 2015;22:2560-6. [DOI: 10.1245/s10434-014-4296-z] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 6.9] [Reference Citation Analysis]
25 Saito T, Kurokawa Y, Miyazaki Y, Makino T, Takahashi T, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y. Which is a more reliable indicator of survival after gastric cancer surgery: Postoperative complication occurrence or C-reactive protein elevation? J Surg Oncol. 2015;112:894-899. [PMID: 26458724 DOI: 10.1002/jso.24067] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
26 Cui HB, Ge HE, Bai XY, Zhang W, Zhang YY, Wang J, Li X, Xing LP, Guo SH, Wang ZY. Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer. Exp Ther Med 2014;7:1083-8. [PMID: 24940391 DOI: 10.3892/etm.2014.1599] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
27 Kanda M, Kodera Y, Sakamoto J. Updated evidence on adjuvant treatments for gastric cancer. Expert Rev Gastroenterol Hepatol. 2015;9:1549-1560. [PMID: 26414453 DOI: 10.1586/17474124.2015.1094373] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
28 Aoyama T. Perioperative body composition changes in the multimodal treatment of gastrointestinal cancer. Surg Today 2020;50:217-22. [PMID: 31028458 DOI: 10.1007/s00595-019-01815-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
29 Ji X, Yang Q, Qin H, Zhou J, Liu W. Tumor blood supply may predict neoadjuvant chemotherapy response and survival in patients with gastric cancer. J Int Med Res. 2019;47:2524-2532. [PMID: 31039658 DOI: 10.1177/0300060519845491] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Jiang Y, Huang W, Xie J, Han Z, Chen C, Xi S, Sun Z, Hu Y, Zhao L, Yu J, Li T, Zhou Z, Cai S, Li G. Young age increases risk for lymph node positivity in gastric cancer: A Chinese multi-institutional database and US SEER database study. J Cancer 2020;11:678-85. [PMID: 31942191 DOI: 10.7150/jca.37531] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
31 Hayashi T, Aoyama T, Tanabe K, Nishikawa K, Ito Y, Ogata T, Cho H, Morita S, Miyashita Y, Tsuburaya A. Low creatinine clearance is a risk factor for D2 gastrectomy after neoadjuvant chemotherapy. Ann Surg Oncol. 2014;21:3015-3022. [PMID: 24715213 DOI: 10.1245/s10434-014-3670-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
32 Yamamoto M, Kurokawa Y, Miyazaki Y, Makino T, Takahashi T, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y. Usefulness of Preoperative Plasma Fibrinogen Versus Other Prognostic Markers for Predicting Gastric Cancer Recurrence. World J Surg. 2016;40:1904-1909. [PMID: 26969673 DOI: 10.1007/s00268-016-3474-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]